19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: T cell lymphoma; leukemia Patient sample and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting TRBC1 could help treat TRBC1-positive T cell lymphomas and T cell leukemias. In cultures of T cells...
19:51 , Nov 13, 2017 |  BC Extra  |  Preclinical News

UCL, Autolus develop CARs against T cell malignancies that partially preserve normal T cells

A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell malignancies without wiping out normal T cells. Autolus Ltd. (London, U.K.) licensed the technology from University College London....
20:53 , Oct 4, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

New Therapeutic Targets and Biomarkers: September 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during September 2017. Therapeutic targets are defined as any protein, gene or other...
21:18 , Sep 29, 2017 |  BioCentury  |  Finance

Fueling up

While crossovers joining Autolus Ltd. ’s series C round don’t necessarily mean the chimeric antigen receptor T cell therapy company will follow fellow Syncona Ltd. (LSE:SYNC) portfolio company Nightstar Therapeutics plc (NASDAQ:NITE) to NASDAQ anytime...